Literature DB >> 21460864

The role of the endothelium in the short-term complications of hematopoietic SCT.

E Carreras1, M Diaz-Ricart.   

Abstract

In this review, we analyse the role of the endothelium in the development of several complications that appear soon after haematopoietic SCT (HSCT). Once it had been demonstrated that sinusoidal damage is the initiating event of the sinusoidal obstruction syndrome, it was considered that other short-term complications with overlapping clinical manifestations, such as capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy, diffuse alveolar haemorrhage and idiopathic pneumonia syndrome, could have an endothelial origin. During HSCT, endothelial cells (ECs) are activated and damaged by several factors, including conditioning, cytokines released by damaged tissues, endotoxins translocated through damaged mucosa, drugs used in the procedure, the engraftment, and--in the allogeneic setting--immunological reactions. The different clinical syndromes that occur could be determined by the predominant phenotypic change in the ECs and the location of this change (organ dependant or systemic). Several translational studies have provided evidence of this endothelial dysfunction on the basis of analysis of soluble markers, soluble forms of adhesion molecules, the enumeration of circulating ECs and microparticles, and morphologic and functional changes induced in cultured ECs. This increased knowledge has opened up a wide range of potential pharmacologic interventions to prevent or treat endothelial damage and, consequently, to improve the outcome of patients receiving HSCT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21460864     DOI: 10.1038/bmt.2011.65

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  79 in total

1.  Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.

Authors:  B Thyagarajan; S Jackson; S Basu; P Jacobson; M D Gross; D J Weisdorf; M Arora
Journal:  Int J Immunogenet       Date:  2012-05-30       Impact factor: 1.466

2.  What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.

Authors:  Marta Palomo; Enrique Mir; Montse Rovira; Ginés Escolar; Enric Carreras; Maribel Diaz-Ricart
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

3.  Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.

Authors:  P D Tsirigotis; I B Resnick; B Avni; S Grisariu; P Stepensky; R Or; M Y Shapira
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

4.  Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

Authors:  J Labrador; L López-Corral; O López-Godino; L Vázquez; M Cabrero-Calvo; R Pérez-López; M Díez-Campelo; F Sánchez-Guijo; E Pérez-López; C Guerrero; I Alberca; M C Del Cañizo; J A Pérez-Simón; J R González-Porras; D Caballero
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 5.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

Review 6.  No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Authors:  Tania Jain; Mark R Litzow
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

7.  Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  S Machida; M Onizuka; M Toyosaki; Y Aoyama; H Kawai; J Amaki; R Hara; A Ichiki; Y Ogawa; H Kawada; K Ando
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 8.  No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Authors:  Tania Jain; Mark R Litzow
Journal:  Blood Adv       Date:  2018-11-27

9.  Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation.

Authors:  S Weischendorff; K Kielsen; H Sengeløv; K Jordan; C H Nielsen; A E Pedersen; L P Ryder; A Juul; K G Müller
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

Review 10.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.